Pain
From the Journals
Cannabis for sleep: Short-term benefit, long-term disruption?
“This suggests that while cannabis may improve overall sleep, it’s also possible that there is a tolerance that develops with either very frequent...
Feature
FDA advisers set high bar for new opioids
Two days of FDA discussion over three new opioids seeking U.S. approval highlighted the barriers these drugs now face.
News from the FDA/CDC
FDA committee rejects oxycodegol, new opioid designed for less abuse
A novel opioid molecule designed to have less abuse potential with slower CNS entry received a unanimous FDA committee turn down.
FDA/CDC
FDA okays ubrogepant for acute migraine treatment
ACHIEVE I and ACHIEVE II demonstrate efficacy.
Conference Coverage
Children may develop prolonged headache after concussion
CHARLOTTE, N.C. – Headache after pediatric concussion may present as migraine, chronic daily headache, tension-type...
Opinion
CBD: What physicians need to know about it
An internist describes the benefits and risks of using cannabidiol to treat various conditions.
News from the FDA/CDC
FDA approves Reyvow for acute migraine treatment
The approval of lasmiditan (Reyvow) is based on a pair of randomized, double-blind, placebo-controlled trials that included more than 3,000...
From the Journals
Sensory feedback may smooth walking with a prosthetic leg
Neural stimulation was associated with faster walking speeds, increased confidence, greater metabolic efficiency, and reduced phantom limb pain....
Literature Review
Migraines linked to higher risk of dementia
People with a history of migraines may be at greater risk of developing Alzheimer’s disease and dementia.
Latest News
CDC, SAMHSA commit $1.8 billion to combat opioid crisis
Some of the funds will be used to help improve overdose monitoring.
Conference Coverage
Galcanezumab benefits patients with migraine and medication overuse
PHILADELPHIA – The monoclonal antibody effectively reduces the number of monthly migraine headache days and...